Philippines

Population 2016  103 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2016</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>22 (22–22)</td>
<td>21 (21–22)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.3 (0–2.6)</td>
<td>0.29 (0–2.5)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>573 (321–895)</td>
<td>554 (311–866)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>6 (2.5–11)</td>
<td>5.9 (2.4–11)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>30 (21–40)</td>
<td>30 (20–39)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Estimated TB incidence by age and sex (thousands)*, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
</tr>
<tr>
<td>Females</td>
</tr>
<tr>
<td>33 (16–50)</td>
</tr>
<tr>
<td>Males</td>
</tr>
<tr>
<td>37 (18–56)</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>70 (35–106)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB case notifications, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cases notified</td>
</tr>
<tr>
<td>Total new and relapse</td>
</tr>
<tr>
<td>% tested with rapid diagnostics at time of diagnosis</td>
</tr>
<tr>
<td>% with known HIV status</td>
</tr>
<tr>
<td>% pulmonary</td>
</tr>
<tr>
<td>% bacteriologically confirmed among pulmonary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Universal health coverage and social protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB treatment coverage (notified/estimated incidence), 2016</td>
</tr>
<tr>
<td>TB patients facing catastrophic total costs, 2017</td>
</tr>
<tr>
<td>TB case fatality ratio (estimated mortality/estimated incidence), 2016</td>
</tr>
<tr>
<td>TB/HIV care in new and relapse TB patients, 2016</td>
</tr>
<tr>
<td>Number (%)</td>
</tr>
<tr>
<td>Patients with known HIV-status who are HIV-positive</td>
</tr>
<tr>
<td>- on antiretroviral therapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug-resistant TB care, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases</td>
</tr>
<tr>
<td>Estimated MDR/RR-TB cases among notified pulmonary TB cases</td>
</tr>
<tr>
<td>(15 000–24 000)</td>
</tr>
<tr>
<td>Estimated % of TB cases with MDR/RR-TB</td>
</tr>
<tr>
<td>% notified tested for rifampicin resistance</td>
</tr>
<tr>
<td>67%</td>
</tr>
<tr>
<td>MDR/RR-TB cases tested for resistance to second-line drugs</td>
</tr>
<tr>
<td>Laboratory-confirmed cases</td>
</tr>
<tr>
<td>Patients started on treatment ****</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment success rate and cohort size</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2015</td>
</tr>
<tr>
<td>263 481</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2015</td>
</tr>
<tr>
<td>7 925</td>
</tr>
<tr>
<td>HIV-positive TB cases registered in 2015</td>
</tr>
<tr>
<td>277</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2014</td>
</tr>
<tr>
<td>2 490</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2014</td>
</tr>
<tr>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB preventive treatment, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of HIV-positive people (newly enrolled in care) on preventive treatment</td>
</tr>
<tr>
<td>% of children (aged &lt; 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB financing, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB budget (US$ millions)</td>
</tr>
<tr>
<td>Funding source: 19% domestic, 53% international, 28% unfunded</td>
</tr>
</tbody>
</table>

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2018-07-24

Data: www.who.int/tb/data